In return for the ex-China rights to its new addition, called velinotamig, Cullinan has agreed to pay Genrix Bio the upfront ...

In8bio Inc. has unveiled INB-600, its next-generation γδ T-cell-based T-cell engager (TCE) platform designed to address one of the shortcomings of current existing γδ TCEs, specifically insufficient ...

The candidate in question is CMG1A46, a dual CD19- and CD20-targeted T cell engager that Chimagen Biosciences is currently evaluating in phase 1 trials for leukemia and lymphoma. However ...

JANX’s proprietary Tumor-Activated T Cell Engager [TRACTr] and Tumor-Activated Immunomodulator [TRACIr] platforms engineer drug candidates designed to overcome the limitations of existing T-cell ...

The FDA cleared an investigational new drug application for CLN-978, a bispecific T cell engager, allowing for a phase 1 trial in patients with active, moderate-to-severe SLE. According to the ...

(RTTNews) - IN8bio, Inc. (INAB) announced the launch of its next-generation Gamma-Delta T-cell engager or TCE platform INB-600, designed to overcome the limitations of existing Gamma-Delta TCE ...

Proprietary platform represents the first known approach capable of sustained γδ T cell expansion, eliminating target cells with robust potency INB-619, a next generation γδ TCE targeting CD19 ...